Cardiovascular data show: Novo Nordisk has been underestimated by the market.
Clear point victory for Semaglutide in the obesity race!
Wegovy data refutes dominance thesis of Eli Lilly!
Reading Time: 1 minute
At the ESC Congress 2025 in Madrid, Novo Nordisk presented new real-world data on the effectiveness of Wegovy (Semaglutide 2.4 mg). The STEER study included more than 21,000 overweight or obese patients with existing cardiovascular diseases but without diabetes. The result is clear: With consistent treatment, Wegovy reduced the risk of heart attack, stroke, or death by 57% compared to Eli Lilly's Tirzepatide (Mounjaro/Zepbound). Even when patients with interruptions in therapy were included, the risk reduction was still 29%. This data sheds...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
